Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003241 · ClinicalTrials.gov registry record · Phase 2

Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors

A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Texas Children's Cancer Center.

Completed
Registry status
Phase 2
Development phase
6
Study locations

NCT00003241 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by Texas Children's Cancer Center. The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003241, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by Texas Children's Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
6
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of phenylacetate in treating children with recurrent or progressive brain tumors.

Interventions

  • DRUG phenylacetate

Study Locations (6)

California

  • Children's Hospital Los Angeles - Los Angeles
  • UCSF Cancer Center and Cancer Research Institute - San Francisco

District of Columbia

  • Children's National Medical Center - Washington D.C.

Maryland

  • Pediatric Oncology Branch - Bethesda

Ohio

  • Cleveland Clinic Cancer Center - Cleveland

Texas

  • Texas Children's Cancer Center - Houston

Trial Details

FieldValue
Start Date 1998-05
Est. Completion 2004-09
Phase Phase 2

Sponsor

Texas Children's Cancer Center

2 total trials

What the Registry Record Tells You About NCT00003241

The ClinicalTrials.gov registry entry for NCT00003241 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Texas Children's Cancer Center, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which phenylacetate is the first listed.

NCT00003241 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT00003241 about?

NCT00003241 is a clinical study titled "Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of phenylacetate in treating children with recurrent or progressive brain tumors.

What is the current status of trial NCT00003241?

This trial is currently completed. It is a Phase 2 study. The study started on 1998-05. Estimated completion is 2004-09.

What conditions does trial NCT00003241 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00003241?

The interventions under investigation include: phenylacetate (DRUG).

Who is sponsoring clinical trial NCT00003241?

This trial is sponsored by Texas Children's Cancer Center, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003241 being conducted?

This trial has 6 study locations across California, District of Columbia, Maryland, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.